These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32945972)

  • 1. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
    Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
    Liu HY; Lee YD; Sridharan S; Choong ES; Le H; Wang W; Khor R; Chu J; Oar A; Mott R; Smart J; Jenkins T; Anderson N; Cross S; Loo KF; Wigg A; Stuart K; Pryor D
    J Med Imaging Radiat Oncol; 2021 Jun; 65(3):365-373. PubMed ID: 33890425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm.
    Guarneri A; Franco P; Trino E; Campion D; Faletti R; Mirabella S; Gaia S; Ragona R; Diotallevi M; Saracco G; Salizzoni M; Ricardi U; Carucci P
    Med Oncol; 2016 Oct; 33(10):104. PubMed ID: 27566310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
    Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
    BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.
    Su TS; Liu QH; Zhu XF; Liang P; Liang SX; Lai L; Zhou Y; Huang Y; Cheng T; Li LQ
    Radiat Oncol; 2021 Apr; 16(1):79. PubMed ID: 33882972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study.
    Choi SH; Lee BM; Kim J; Kim DY; Seong J
    J Hepatol; 2024 Jul; 81(1):84-92. PubMed ID: 38467379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of BCLC stage C hepatocellular carcinoma: Results of a single-institutional experience on stereotactic body radiation therapy.
    Que J; Lin CH; Lin LC; Ho CH
    Medicine (Baltimore); 2020 Aug; 99(32):e21561. PubMed ID: 32769898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
    Gkika E; Schultheiss M; Bettinger D; Maruschke L; Neeff HP; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
    Radiat Oncol; 2017 Jul; 12(1):116. PubMed ID: 28701219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
    Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
    Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
    Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
    Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
    Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence.
    Berkovic P; Gulyban A; Nguyen PV; Dechambre D; Martinive P; Jansen N; Lakosi F; Janvary L; Coucke PA
    Clin Colorectal Cancer; 2017 Dec; 16(4):349-357.e1. PubMed ID: 28462852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.